Brain tumors: New vaccine offers patients hope for more time

A therapeutic vaccine targeting IDH1 genetic mutations in high-grade astrocytomas showed 66% of 33 patients alive after 8 years and 42% tumor-free during that period—a marked improvement over the typical 5-year survival for aggressive brain tumors—with long-term follow-up results published in Nature.

Study involved only 33 patients; broader effectiveness and wider applicability remain to be established.